Propanc Biopharma, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a PPCB research report →
Companywww.propanc.com
Propanc Biopharma, Inc. , a biopharmaceutical company, focuses on the development of cancer treatments for patients with pancreatic, ovarian, and colorectal cancer in Australia. Its lead product is PRP, a formulation that is in preclinical phase of development designed to enhance the anti-cancer effects of multiple enzymes acting synergistically.
- CEO
- James Nathanielsz
- IPO
- 2012
- Employees
- 1
- HQ
- Camberwell, VIC, AU
Price Chart
Valuation
- Market Cap
- $1.54M
- P/E
- -0.09
- P/S
- 0.00
- P/B
- 0.16
- EV/EBITDA
- -0.15
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -151.28%
- ROIC
- -161.15%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-58,923,300 · -3135.77%
- EPS
- $-371.25 · 98.95%
- Op Income
- $-57,278,131
- FCF YoY
- 56.67%
Performance & Tape
- 52W High
- $270.25
- 52W Low
- $1.56
- 50D MA
- $2.65
- 200D MA
- $29.20
- Beta
- 3.40
- Avg Volume
- 139.91K
Get TickerSpark's AI analysis on PPCB
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jul 5, 23 | ZELINGER JOSEF | other | 15,000,000 |
| Aug 17, 21 | Kenyon Julian Norman | other | 3,420,000 |
| Aug 17, 21 | Nathanielsz James Andrew | other | 5,928,000 |
| Aug 17, 21 | Nathanielsz James Andrew | other | 2,800,000 |
| Aug 17, 21 | ZELINGER JOSEF | other | 0 |
| Jun 24, 19 | Campiciano Carlo M | other | 0 |
| May 14, 19 | Kenyon Julian Norman | other | 9,750,000 |
| May 14, 19 | Kenyon Julian Norman | other | 9,750,000 |
| May 14, 19 | Nathanielsz James Andrew | other | 19,500,000 |
| May 14, 19 | Nathanielsz James Andrew | other | 19,500,000 |
Our PPCB Coverage
We haven't published any research on PPCB yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate PPCB Report →